STEPAN CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STEPAN CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $1.80B | Feb 27, 2013 |
| FY2012 | Dec 31, 2011 | $1.84B | Feb 27, 2013 |
| FY2012 | Dec 31, 2010 | $1.43B | Feb 27, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.33B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.18B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.33B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.77B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.35B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.87B | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $444.99M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $451.58M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $473.00M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $489.17M | Feb 27, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $473.82M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $487.81M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $495.10M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $468.27M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $420.64M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $445.03M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $454.60M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $445.90M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $419.29M | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | $444.01M | Feb 24, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $272.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $277.60M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $427.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $395.81M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $383.61M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $84.74M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $77.40M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $92.96M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $84.61M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $50.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $40.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $147.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $137.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $126.77M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $22.04M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $25.89M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $30.22M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $24.98M | Feb 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $70.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $58.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $207.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $170.78M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $171.52M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $28.49M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $27.97M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $41.07M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $29.74M | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $35.73M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $40.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $38.78M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $36.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $34.14M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $33.52M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $33.17M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $34.86M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $162.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $174.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $160.76M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $72.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $235.22M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $218.43M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $171.13M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $198.86M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $212.16M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.51M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $122.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $260.34M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $301.55M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $194.48M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $125.79M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $105.57M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $86.65M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $78.61M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $103.08M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.36B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.30B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.36B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.43B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.07B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.75B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.58B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.51B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.50B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.35B | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.17B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.22B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.17B | Feb 26, 2026 |
| FY2022 | Dec 31, 2021 | $1.07B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $986.69M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $891.78M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $807.43M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $740.10M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $634.60M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.57M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $91.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $97.44M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $95.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $97.19M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $27.97M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $26.09M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $22.95M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $25.12M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $25.31M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.27B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.26B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.25B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.02B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $922.46M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $837.11M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $721.74M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $649.07M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $99.67M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $129.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $173.75M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $159.19M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $349.94M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $315.38M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $300.19M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $298.89M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $225.74M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $626.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $625.44M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $654.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $587.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $363.58M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $198.67M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $222.10M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $276.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $290.80M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $317.01M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 5 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 4 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | 3 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 5 | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 1 | Feb 27, 2020 |